Cisplatin Plus Standard-of-Care Regimen Reduced Tumors in Advanced Pancreatic Cancer
Diagnoses of pancreatic cancer typically occur at later stages of the disease, hindering therapy.
The addition of cisplatin to standard-of-care gemcitabine/nab-paclitaxel drug treatment improved shrinkage of tumors in patients with metastatic pancreatic cancer.
Results from this phase 1b/2 clinical trial, presented at the 2017 Gastrointestinal Cancers Symposium, indicated that 3 treatment cycles decreased tumor markers and resulted in significant tumor shrinkage in just 9 weeks.
"After treatment, 2 patients had no evidence of disease and are alive over 3 years after starting this regimen. This is very rare with traditional chemotherapy," said Gayle Jameson, nurse practitioner and principal investigator of the clinical trial.
Twenty-four patients were evaluated. Median overall survival (OS) was 16.5 months, which exceeds the historical median OS of 6 to 12 months with standard chemotherapy.
Nearly three-quarters of patients (71%) experienced a reduction in tumor size of at least 30%. Of these 17 patients, 2 experienced complete response.
This trial began in 2013. Stand Up To Cancer, Mattress Firm, the Arizona Diamondbacks, and the Seena Magowitz Foundation funded this study.
Diagnoses of pancreatic cancer frequently occur at later stages of the disease, making it hard to treat. Only approximately one-quarter of patients with the disease survive more than 1 year, and less than 10% survive longer than 5 years.
1. TGen-HonorHealth Research Institute clinical trial reports high rate of tumor shrinkage among patients with advanced pancreatic cancer [press release]. Scottsdale, AZ; April 25, 2017. https://www.tgen.org/home/news/2017-media-releases/tgen-honorhealth-pancreatic-cancer-results.aspx#.WRIkDbzyuuW. Accessed May 9, 2017.